New drug shows promise for rare skin disease over nearly 5 years
NCT ID NCT03886246
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at the long-term safety and effectiveness of spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study and will continue treatment for up to 5 years. Researchers will monitor side effects and how quickly symptoms improve during flare-ups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
spesolimab
What this could lead to
If successful, this could confirm spesolimab as a safe long-term treatment to control GPP flares and improve symptoms.
What could go wrong
This is a Phase 2 open-label study with no placebo group, so results may not prove effectiveness definitively. Long-term safety data is still being collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Skin Research, Testing and Product Development
Makati City, 1229, Philippines
-
Chang Gung Medical Foundation (CGMF) - Linkou Bran
Linkou District, 333, Taiwan
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Clínica Dermacross S.A.
Vitacura, 7640881, Chile
-
FSBEI HE "Kirov State Medical University"
Kirov, 610035, Russia
-
Fachklinik Bad Bentheim
Bad Bentheim, 48455, Germany
-
Farhat Hached Hospital
Sousse, 4000, Tunisia
-
HCMC Hospital of Dermato-Venereology-Ho Chi Minh-66092
Ho Chi Minh City, 70000, Vietnam
-
HOP Robert Debré
Reims, 51092, France
-
HOP Saint-André
Bordeaux, 33000, France
-
HOP Saint-Louis
Paris, 75010, France
-
Hedi Chaker Hospital, Department of Dermatology
Tunisia, 1053, Tunisia
-
Hospital Italiano de Buenos Aires
CABA, C1199ABD, Argentina
-
Hospital Kuala Lumpur
Kuala Lumpur, 50586, Malaysia
-
Hospital Pakar Sultanah Fatimah
Muar town, 84000, Malaysia
-
Hospital Pulau Pinang-Pulau Pinang-21953
George Town, 10990, Malaysia
-
Hospital Raja Permaisuri Bainun
Ipoh, 30450, Malaysia
-
Hospital Sant Joan de Déu
Esplugues Del Llobregat, 08950, Spain
-
Hospital Selayang
Kuala Selangor, 68100, Malaysia
-
Hospital Sultan Ismail
Johor Bahru, 81100, Malaysia
-
Hospital Sultanah Aminah
Johor Bahru, 80100, Malaysia
-
Hospital Universitario Dr Jose Eleuterio Gonzalez
Monterrey, 64460, Mexico
-
Huashan Hospital, Fudan University
Shanghai, 200040, China
-
Hôpital de l'Archet
Nice, 06200, France
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Iloilo Doctors Hospital
Iloilo City, Iloilo, 5000, Philippines
-
Institute of Dermatology
Bangkok, 10400, Thailand
-
Istituto Clinico Humanitas
Rozzano (MI), 20089, Italy
-
Klinikum Oldenburg AöR
Oldenburg, 26133, Germany
-
Klinikum der Universität München - Campus Innenstadt
München, 80337, Germany
-
LLC "Medical Center Azbuka Zdorovia"
Kazan', 420111, Russia
-
LLC Skin Disease Clinic of Pier Volkenstein, St. Petersburg
Saint Petersburg, 190123, Russia
-
La Rabta Hospital
Tunis, 1007, Tunisia
-
Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi
Istanbul, 34890, Turkey (Türkiye)
-
Nagoya City University Hospital
Aichi, Nagoya, 467-8602, Japan
-
National Hospital of Dermatology and Venereology
Hà Nội, 10000, Vietnam
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Oakland Hills Dermatology
Auburn Hills, Michigan, 48326, United States
-
Queen Elizabeth Hospital
Kota Kinabalu, 88586, Malaysia
-
Ramathibodi Hospital
Bangkok, 10400, Thailand
-
SBHI Chelyabinsk Reg.Clin.Derma.Dispen.
Chelyabinsk, 454048, Russia
-
Saitama Medical University Hospital
Saitama, Iruma-gun, 350-0495, Japan
-
Saratov State Med.Univ.n.a.Razumovskogo
Saratov, 410028, Russia
-
Sarawak General Hospital
Kuching, Sarawak, 93586, Malaysia
-
Second Affiliated Hospital of Xi'an JiaoTong University
Xi'an, 710004, China
-
Severance Hospital
Seoul, 03722, South Korea
-
Shanghai Skin Disease Hospital
Shanghai, 200000, China
-
Singapore General Hospital
Singapore, 169608, Singapore
-
Southern Philippines Medical Center -Davao-62091
Davao City, 8000, Philippines
-
Sun yet-sen Memorial Hospital, Sun yet-sen Univesity
Guangzhou, 510288, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, 310009, China
-
Tokyo Medical University Hachioji Medical Center
Tokyo, Hachioji, 193-0998, Japan
-
Tokyo Medical University Ibaraki Medical Center
Ibaraki, Inashiki-gun, 300-0395, Japan
-
Universitätsklinikum Bonn AöR
Bonn, 53127, Germany
-
Universitätsklinikum Frankfurt
Frankfurt am Main, 60596, Germany
-
Westfälische Wilhelms-Universität Münster
Münster, 48149, Germany